Education
About Us
Working with TipRanks
Follow Us
NanoCarrier Co., Ltd. (JP:4571)
:4571
RESEARCH TOOLSreports
Top Page
NanoCarrier Co., Ltd.
(Frankfurt:4571)
36Underperform
NanoCarrier Co., Ltd. (4571) vs. S&P 500 (SPY)
Market Cap
€9.25B
Dividend YieldN/A
Average Volume (3M)878.55K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth-30.46%
EPS Growth39.41%
CountryJP
Employees24
SectorHealthcare
Sector Strength69
IndustryBiotechnology
Share Statistics
EPS (TTM)-9.05
Shares Outstanding70,625,460
10 Day Avg. Volume1,237,040
30 Day Avg. Volume878,550
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NanoCarrier Co., Ltd. Business Overview & Revenue Model
Company DescriptionNanoCarrier Co., Ltd. is a Japanese biopharmaceutical company that specializes in the development and commercialization of innovative nanotechnology-based drug delivery systems. The company focuses on creating highly effective and targeted treatments for cancer and other severe diseases through its proprietary micellar nanoparticle technology. NanoCarrier is committed to advancing healthcare by improving the efficacy and safety profiles of therapeutic agents.
How the Company Makes MoneyNanoCarrier Co., Ltd. generates revenue primarily through the development, licensing, and commercialization of its proprietary drug delivery systems. The company collaborates with pharmaceutical companies to co-develop drugs using its nanotechnology platforms, earning revenues from licensing fees, milestone payments, and royalties on sales of co-developed products. Additionally, NanoCarrier may receive funding from government grants or private investments to support its research and development activities. Strategic partnerships and collaborations with other biotech and pharmaceutical companies also play a significant role in enhancing its market reach and financial performance.
NanoCarrier Co., Ltd. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 114.20M | 135.51M | 202.19M | 264.03M | 313.26M | 552.97M | Gross Profit |
| 78.97M | 110.96M | 159.60M | 222.74M | 274.89M | 475.01M | EBIT |
| -662.03M | -864.41M | -1.25B | -2.06B | -1.30B | -1.11B | EBITDA |
| -661.00M | -863.00M | -1.30B | -2.06B | -1.30B | -1.10B | Net Income Common Stockholders |
| -637.63M | -780.00M | -1.31B | -1.88B | -2.84B | -2.01B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.52B | 4.28B | 4.44B | 5.95B | 6.40B | 7.47B | Total Assets |
| 4.18B | 5.07B | 5.78B | 7.14B | 7.82B | 8.94B | Total Debt |
| 540.00M | 1.11B | 1.11B | 1.15B | 0.00 | 0.00 | Net Debt |
| -1.78B | -968.72M | -1.70B | -2.40B | -3.89B | -4.47B | Total Liabilities |
| 1.20B | 1.65B | 1.53B | 1.57B | 321.00M | 175.60M | Stockholders Equity |
| 2.98B | 3.42B | 4.25B | 5.57B | 7.50B | 8.77B |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | -585.08M | -1.09B | -1.76B | -1.25B | -1.14B | Operating Cash Flow |
| 0.00 | -585.08M | -1.09B | -1.75B | -1.25B | -1.14B | Investing Cash Flow |
| 0.00 | 793.01M | 1.21B | -244.13M | -871.69M | -112.34M | Financing Cash Flow |
| 0.00 | 3.73M | 32.20M | 1.15B | -11.46M | 2.16B |
NanoCarrier Co., Ltd. Technical Analysis
Negative
131.00
Price Trends
142.10
Negative
145.44
Negative
164.09
Negative
Market Momentum
-2.91
Negative
45.96
Neutral
33.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 131 is below the 20-day moving average (MA) of 132.25, below the 50-day MA of 142.10, and below the 200-day MA of 164.09, indicating a bearish trend. The MACD of -2.91 indicates Negative momentum. The RSI at 45.96 is Neutral, neither overbought nor oversold. The STOCH value of 33.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.
NanoCarrier Co., Ltd. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
87 Outperform | $1.90T | 10.90 | 13.11% | 2.50% | 1.58% | 12.48% | |
76 Outperform | $5.83T | 24.06 | 17.60% | 1.80% | 17.77% | 48.97% | |
62 Neutral | ¥32.70B | 12.45 | 3.14% | 8.07% | -31.98% | ||
55 Neutral | ¥10.21B | ― | ― | 63.45% | -52.65% | ||
51 Neutral | ¥7.60B | ― | ― | -56.12% | -73.82% | ||
51 Neutral | $5.32B | 3.39 | -40.26% | 2.89% | 17.93% | 2.48% | |
36 Underperform | €9.25B | ― | -19.08% | ― | -30.46% | 39.41% |
* Healthcare Sector Average
Performance Comparison
JP:4571
NanoCarrier Co., Ltd.
131.00
-50.00
-27.62%
JP:4577
Daito Pharmaceutical Co., Ltd.
2,042.00
-406.93
-16.62%
JP:4579
RaQualia Pharma Inc.
418.00
-177.00
-29.75%
JP:4582
Symbio Pharmaceuticals Limited
154.00
-20.00
-11.49%
JP:4507
Shionogi & Co
2,404.50
8.79
0.37%
JP:4568
Daiichi Sankyo Company
3,523.00
-1,765.31
-33.38%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.